JP2024515879A5 - - Google Patents
Info
- Publication number
- JP2024515879A5 JP2024515879A5 JP2023566870A JP2023566870A JP2024515879A5 JP 2024515879 A5 JP2024515879 A5 JP 2024515879A5 JP 2023566870 A JP2023566870 A JP 2023566870A JP 2023566870 A JP2023566870 A JP 2023566870A JP 2024515879 A5 JP2024515879 A5 JP 2024515879A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence described
- siglec
- cancer
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163182271P | 2021-04-30 | 2021-04-30 | |
| US63/182,271 | 2021-04-30 | ||
| PCT/US2022/027006 WO2022232558A1 (en) | 2021-04-30 | 2022-04-29 | Anti-siglec compositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515879A JP2024515879A (ja) | 2024-04-10 |
| JP2024515879A5 true JP2024515879A5 (enExample) | 2025-03-17 |
Family
ID=83848703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566870A Pending JP2024515879A (ja) | 2021-04-30 | 2022-04-29 | 抗ｓｉｇｌｅｃ組成物及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240218067A1 (enExample) |
| EP (1) | EP4329806A4 (enExample) |
| JP (1) | JP2024515879A (enExample) |
| KR (1) | KR20240006519A (enExample) |
| CN (1) | CN117355331A (enExample) |
| AU (1) | AU2022267362A1 (enExample) |
| CA (1) | CA3216324A1 (enExample) |
| IL (1) | IL308137A (enExample) |
| MX (1) | MX2023012759A (enExample) |
| TW (1) | TW202305005A (enExample) |
| WO (1) | WO2022232558A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117643575B (zh) * | 2023-11-03 | 2026-04-24 | 中山大学 | 一种纳米材料及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120171114A1 (en) * | 2008-04-11 | 2012-07-05 | Haeuw Jean-Francois | Anti-cd151 antibodies and their use in the treatment of cancer |
| US8163281B2 (en) * | 2009-03-04 | 2012-04-24 | The Regents Of The University Of Michigan | Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis |
| WO2015107171A1 (en) * | 2014-01-17 | 2015-07-23 | Sanofi | Methods of identifying patients suffering from liver cancer who will most likely benefit from a treatment with an antagonist anti-fgfr4 antibody |
| CA3004972A1 (en) * | 2015-11-17 | 2017-05-26 | Innate Pharma | Siglec-10 antibodies |
| EP3947460A4 (en) * | 2019-03-26 | 2023-05-10 | Forty Seven, Inc. | MULTISPECIFIC AGENTS FOR TREATMENT OF CANCER |
-
2022
- 2022-04-29 EP EP22796839.3A patent/EP4329806A4/en active Pending
- 2022-04-29 AU AU2022267362A patent/AU2022267362A1/en active Pending
- 2022-04-29 JP JP2023566870A patent/JP2024515879A/ja active Pending
- 2022-04-29 US US18/558,112 patent/US20240218067A1/en active Pending
- 2022-04-29 TW TW111116333A patent/TW202305005A/zh unknown
- 2022-04-29 MX MX2023012759A patent/MX2023012759A/es unknown
- 2022-04-29 CA CA3216324A patent/CA3216324A1/en active Pending
- 2022-04-29 WO PCT/US2022/027006 patent/WO2022232558A1/en not_active Ceased
- 2022-04-29 KR KR1020237036789A patent/KR20240006519A/ko active Pending
- 2022-04-29 CN CN202280031124.9A patent/CN117355331A/zh active Pending
- 2022-04-29 IL IL308137A patent/IL308137A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI786044B (zh) | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 | |
| TWI596116B (zh) | 包含專一性辨識ｃｄ３８之抗體及硼替佐米（ｂｏｒｔｅｚｏｍｉｂ）之抗腫瘤組合 | |
| US20180036395A1 (en) | Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies | |
| JP2022532490A5 (enExample) | ||
| BR112018012801B1 (pt) | Usos de uma combinação de anticorpos anti-pd-1 e anticorpos biespecíficos anti-cd20/anti-cd3 e de uma composição farmacêutica | |
| JP2021511372A5 (enExample) | ||
| CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| NZ720515A (en) | Methods of treating cancers using pd-1 axis binding antagonists and taxanes | |
| JP2020508317A5 (enExample) | ||
| JP2018522851A5 (enExample) | ||
| JP2010515709A5 (enExample) | ||
| JP2021528423A5 (enExample) | ||
| JP2022511394A5 (enExample) | ||
| JP2023526224A5 (enExample) | ||
| CN121943909A (zh) | 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用 | |
| KR20160050026A (ko) | 항 종양제 및 항 종양 효과 증강제 | |
| JP2024515879A5 (enExample) | ||
| Hwang et al. | Emerging egfr-targeted therapy in head and neck cancer: A review | |
| TW202545570A (zh) | 抗體藥物偶聯物和免疫檢查點抑制劑的聯合應用 | |
| WO2025082449A1 (zh) | 抗体药物偶联物和免疫检查点抑制剂的联合应用 | |
| CN111065412B (zh) | Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途 | |
| JP2022531894A5 (enExample) | ||
| Tempero et al. | Immunotherapy with monoclonal antibody (Mab) in pancreatic adenocarcinoma | |
| TW201922292A (zh) | 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途 | |
| HK40124723A (zh) | 抗体药物偶联物和免疫检查点抑制剂的联合应用 |